General Information of Drug (ID: DMH2NMY)

Drug Name
Mepivacaine
Synonyms
Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE
Indication
Disease Entry ICD 11 Status REF
Analgesia MB40.8 Approved [1]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 246.35
Logarithm of the Partition Coefficient (xlogp) 1.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
55% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 6.8 mL/min/kg [4]
Elimination
5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.9 - 3.2 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 23.195 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.3% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 2.4 mg/mL [2]
Chemical Identifiers
Formula
C15H22N2O
IUPAC Name
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
Canonical SMILES
CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
InChI
InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
InChIKey
INWLQCZOYSRPNW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4062
ChEBI ID
CHEBI:6759
CAS Number
96-88-8
DrugBank ID
DB00961
TTD ID
D0WO8W
ACDINA ID
D01238
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mepivacaine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bretylium DM1FX74 Moderate Increased risk of atrioventricular block by the combination of Mepivacaine and Bretylium. Ventricular tachyarrhythmia [BC71] [8]
Amiodarone DMUTEX3 Moderate Increased risk of atrioventricular block by the combination of Mepivacaine and Amiodarone. Ventricular tachyarrhythmia [BC71] [8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Potassium chloride E00074 4873 Tonicity agent
Calcium chloride E00474 5284359 Antimicrobial preservative; Desiccant
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mepivacaine 10mg/1ml solution 10mg/1ml Solution Epidural Infiltration
Mepivacaine 30mg/ml solution 30mg/ml Solution Intravenous
Mepivacaine 30mg/ml solution 30mg/ml Solution Subcutaneous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
7 Long QT 1 mutation KCNQ1A344V increases local anesthetic sensitivity of the slowly activating delayed rectifier potassium current. Anesthesiology. 2006 Sep;105(3):511-20. doi: 10.1097/00000542-200609000-00015.
8 Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]